venetoclax-idh inhibitor combination therapy for aml
Published 5 years ago • 165 plays • Length 3:08Download video MP4
Download video MP3
Similar videos
-
1:23
decitabine, venetoclax, and idh inhibitor in idh-mutated aml
-
1:18
venetoclax combination therapies in aml
-
5:35
venetoclax plus hmas in idh-mutant aml
-
1:40
pivekimab sunirine in combination with venetoclax and azacitidine for cd123-positive aml
-
2:31
idh mutations in aml treated with venetoclax
-
1:36
the synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating aml
-
2:20
pevonedistat, azacitidine and venetoclax triplet therapy for aml, mds and cmml
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
12:05
venetoclax combinations, safety and efficacy
-
9:21
automated blood analyser: part 8 haematology
-
4:52
apoptosis and venetoclax
-
6:52
ivosidenib and venetoclax /- azacitidine for idh1-mutated hematologic malignancies
-
1:56
clinical trials investigating venetoclax combinations for aml
-
4:11
venetoclax based combination therapy in aml: a real-world retrospective analysis
-
3:33
targeting bcl-2 in older aml: novel venetoclax combinations
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
3:53
investigating the combination of pivekimab sunirine, azacitidine & venetoclax in r/r aml
-
3:57
the efficacy of flt3 and idh1/2 inhibitors in patients with aml previously treated with venetoclax
-
3:35
safety and efficacy of venetoclax-based regimens for aml
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:12
cpx-351 with venetoclax in r/r aml: results of a phase ib study
-
2:45
imgn632 plus venetoclax and/or azacitidine for patients with cd123-positive aml